Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
Article first published online: 27 FEB 2013
Copyright © 2013 FEND. Published by John Wiley & Sons, Ltd.
European Diabetes Nursing
Volume 10, Issue 1, pages 31–36, March 2013
How to Cite
Ahrén, B. (2013), Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Eur. Diab. Nursing, 10: 31–36. doi: 10.1002/edn.221
- Issue published online: 27 FEB 2013
- Article first published online: 27 FEB 2013
- Manuscript Accepted: 5 DEC 2012
- Manuscript Received: 2 DEC 2012
- incretin hormones;
- type 2 diabetes
Incretin therapy is a glucose-lowering therapy which has attracted great interest during recent years. It is based on the antidiabetic action of the incretin hormone glucagon-like peptide-1 (GLP-1), which involves both stimulation of insulin secretion and inhibition of glucagon secretion. This results in lowering of both fasting and postprandial glycaemia. Incretin therapy is either with GLP-1 receptor agonists or with inhibitors of dipeptidyl peptidase-4 (DPP-4), which is the enzyme which inactivates endogenous GLP-1. The GLP-1 receptor agonists are injected subcutaneously once or twice daily or once weekly. The DPP-4 inhibitors are oral tablets taken once or twice daily. Both therapies reduce HbA1c without weight gain, and for GLP-1 receptor agonists with a weight reduction. Incretin therapy is safe with very few adverse events and an additional value of the therapy is a very low risk for hypoglycaemia. Incretin therapy is efficient both in monotherapy and in combination with metformin, sulphonylureas, thiazolidinediones and insulin. Its main indication is as add-on to metformin in patients who are insufficiently controlled on metformin alone, and an important indication is also in combination with insulin therapy. The experienced value of incretin therapy for patient care will most likely result in increased use of this therapy during the coming years. Copyright © 2013 FEND. Published by John Wiley & Sons, Ltd.